Home GPCR & G Protein Endothelin Receptor antagonist Sparsentan (PS-433540, RE-021)

research use only

Sparsentan (PS-433540, RE-021) Endothelin Receptor antagonist

Cat.No.S6665

Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.
Sparsentan (PS-433540, RE-021) Endothelin Receptor antagonist Chemical Structure

Chemical Structure

Molecular Weight: 592.75

Jump to

Quality Control

Batch: S666501 DMSO]100 mg/mL]false]Ethanol]40 mg/mL]false]Water]Insoluble]false Purity: 99.71%
99.71

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (168.7 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 40 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 592.75 Formula

C32H40N4O5S

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 254740-64-2 -- Storage of Stock Solutions

Synonyms DARA SMILES CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
endothelin type A receptor
angiotensin II type 1 receptor
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-03)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04663204 RECRUITING
Immunoglobulin A Nephropathy; Kidney Diseases; Glomerulonephritis, IGA; Glomerulonephritis; Autoimmune Diseases; Immune System Diseases
University of Leicester
 2020-12-10 PHASE2
NCT05003986 RECRUITING
Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy; IgA Vasculitis; Alport Syndrome
Travere Therapeutics, Inc.
 2021-08-12 PHASE2
NCT07219121 ACTIVE_NOT_RECRUITING
Proteinuria; Immunoglobulin A (IgA) Nephropathy; Focal Segmental Glomerulosclerosis; Kidney Transplant
Travere Therapeutics, Inc.
 2025-10-07 PHASE4
NCT07224776 RECRUITING
Proteinuric Renal Disease; Proteinuric Kidney Disease; Proteinuria; Proteinuria in Nephrotic Range
Brigham and Women's Hospital
 2026-07-10 PHASE1
NCT05856760 COMPLETED
Immunoglobulin A Nephropathy
Travere Therapeutics, Inc.
 2023-05-19 PHASE2
NCT05630612 ACTIVE_NOT_RECRUITING
ANCA Associated Vasculitis; Cardiovascular Diseases; Kidney Diseases
University of Edinburgh
 2022-12-08 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map